These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

933 related items for PubMed ID: 30497883

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [Abstract] [Full Text] [Related]

  • 5. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.
    Cochrane Database Syst Rev; 2014 Jun 30; 2014(6):CD009266. PubMed ID: 24979481
    [Abstract] [Full Text] [Related]

  • 6. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
    Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, Xiang S, Wang S.
    Prostate Cancer Prostatic Dis; 2018 Nov 30; 21(4):451-460. PubMed ID: 29988099
    [Abstract] [Full Text] [Related]

  • 7. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
    Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, Adolfsson J, Robinson D, Stattin P.
    Eur Urol; 2017 Dec 30; 72(6):920-928. PubMed ID: 28711383
    [Abstract] [Full Text] [Related]

  • 8. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, Polard E, Nowak E, Oger E.
    Eur J Cancer; 2017 May 30; 77():99-108. PubMed ID: 28390298
    [Abstract] [Full Text] [Related]

  • 9. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.
    J Clin Oncol; 2015 Apr 10; 33(11):1243-51. PubMed ID: 25732167
    [Abstract] [Full Text] [Related]

  • 10. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).
    Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, López-Campos F, Ost P, Roumeguere TA, Herrera-Imbroda B, D'Hondt LA, Quivrin M, Gontero P, Villà S, Khaled H, Fournier B, Musoro J, Krzystyniak J, Pretzenbacher Y, Loriot Y.
    Eur Urol Oncol; 2024 Oct 10; 7(5):1051-1060. PubMed ID: 38272747
    [Abstract] [Full Text] [Related]

  • 11. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
    Sanford NN, Chen MH, Loffredo M, Renshaw A, Kantoff PW, D'Amico AV.
    Prostate Cancer Prostatic Dis; 2017 Mar 10; 20(1):79-84. PubMed ID: 27824043
    [Abstract] [Full Text] [Related]

  • 12. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK, Keane TE.
    Curr Urol Rep; 2017 Jun 10; 18(6):41. PubMed ID: 28417429
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL, O'Malley AJ, Freedland SJ, Smith MR.
    J Natl Cancer Inst; 2010 Jan 06; 102(1):39-46. PubMed ID: 19996060
    [Abstract] [Full Text] [Related]

  • 20. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
    O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, Van Hemelrijck M.
    BJU Int; 2016 Sep 06; 118(3):391-8. PubMed ID: 26497726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.